

Supplementary Table 1. IL-33 primer sequence


Gene	Primer/probe name	Sequence 5'-3'
IL-33	rs16924159-F	TCTTGGGTCAGTGCTCTTTGTA
	rs16924159-R	CTCAAAGTATGTGAGGCATGGGA
	rs16924159-P/G	*FAM-TGTGGCTCTGCAGTTT
	rs16924159-P/A	*HEX-CTGTGGCTCTGTAGTTTTA

IL-33: interleukin-33, rs: reference single nucleotide polymorphism, F: forward primer, R: reverse primer, P/G and P/A: probes. *FAM and *HEX: fluorescent reporter dyes commonly used in TaqMan allelic discrimination assays during real-time polymerase chain reaction.

Supplementary Table 2. CDAI score distribution across infliximab and etanercept brands

Trademarks of *infliximab and *etanercept	CDAI score (n=100)				Total	p-value
	Remission	Low	Moderate	High		
Remicade (infliximab)	0 (0)	5 (71.43)	0 (0)	2 (28.57)	7 (100)	0.037
Ixifi (infliximab)	1 (9.09)	2 (18.19)	4 (36.36)	4 (36.36)	11 (100)	
Remsima (infliximab)	0 (0)	4 (19.05)	10 (47.62)	7 (33.33)	21 (100)	
Enbrel (etanercept)	3 (4.92)	10 (16.39)	16 (26.23)	32 (52.46)	61 (100)	

Values are presented as number (%). CDAI: clinical disease activity index. Remicade: original infliximab, Ixifi: biosimilar infliximab, Remsima: biosimilar infliximab, Enbrel: original etanercept. *Infliximab and *etanercept: tumor necrosis factor inhibitor types.



Supplementary Figure 1. Amplification plot for IL-33 (rs16924159).
 IL-33: interleukin-33, rs: reference single nucleotide polymorphism,
 G: wild-type allele, A: mutant allele.